Composite Glucocorticoid Regulation at a Functionally Defined Negative Glucocorticoid Response Element of the Human Corticotropin-Releasing Hormone Gene
Stephen P. Malkoski and
Richard I. Dorin
Departments of Medicine and Biochemistry and Molecular Biology
Albuquerque Veterans Administration Medical Center and University
of New Mexico Health Sciences Center Albuquerque, New Mexico
87108
 |
ABSTRACT
|
---|
Glucocorticoid-dependent negative feedback
of the hypothalamic-pituitary-adrenal axis is mediated in part
through direct inhibition of hypothalamic CRH gene transcription. In
the present study, we sought to further localize and characterize
glucocorticoid receptor (GR) and AP-1 interactions at a functionally
defined negative glucocorticoid response element (nGRE) of the CRH
promoter. Transient transfection studies in mouse corticotroph AtT-20
cells demonstrated that internal deletion of the nGRE (-278 to -249
nucleotides) within the context of 1 kb of the intact CRH promoter
resulted in decreased 8-Br-cAMP stimulation and
glucocorticoid-dependent repression of CRH promoter activity. The nGRE
conferred transcriptional activation by both cAMP and overexpressed
c-jun or c-fos AP-1 nucleoproteins as well as
specific glucocorticoid-dependent repression to a heterologous
promoter. A similar profile of regulation was observed for the
composite GRE derived from mouse proliferin promoter. The CRH nGRE was
clearly distinct from the consensus cAMP response element (CRE) at
-224 nucleotides, which increased basal activity and cAMP
responsiveness of a heterologous promoter but did not confer
glucocorticoid-dependent repression. High-affinity binding sites for
both GR and AP-1 nucleoproteins were identified at adjacent elements
within the nGRE. Mutations that disrupted either GR or AP-1 binding
activity were associated with loss of glucocorticoid-dependent
repression. These results are consistent with a composite mechanism of
glucocorticoid-dependent repression involving direct DNA binding of GR
and AP-1 nucleoproteins at discrete adjacent sites within the CRH
promoter.
 |
INTRODUCTION
|
---|
Hypothalamic CRH-producing neurons integrate afferent central
nervous system signals related to stress responsiveness and circadian
rhythmicity as well as negative feedback inhibition by glucocorticoids
(1, 2). The primacy of CRH in central regulation of the
hypothalamic-pituitary-adrenal (HPA) axis is established in animal and
human models of CRH deficiency and excess. The CRH knockout mouse
demonstrates low levels of ACTH and corticosterone and a blunted HPA
response. Thus, even in the setting of reduced corticosteroid feedback,
other ACTH secretagogues, such as vasopressin, are unable to compensate
for CRH deficiency (3, 4). Within the clinical model of Cushings
syndrome, the prolonged suppression of ACTH and cortisol secretion that
remains after chronic corticosteroid excess can be reversed by
administration of exogenous CRH, indicating that repression of central
signals limits recovery of the HPA axis (5).
Data suggest that hypothalamic CRH repression is mediated, in part,
through direct effects on hypothalamic CRH-producing neurons (6, 7),
which express high levels of classical (type II) glucocorticoid
receptor (GR) (8). However, other sites of corticosteroid action may
contribute to repression of hypothalamic CRH, as both GR and
corticosteroid-responsive mineralocorticoid receptors are
expressed in extrahypothalamic central nervous system sites (9, 10).
Glucocorticoids appear to regulate CRH through direct inhibition of
gene transcription (11). This effect is tissue specific; CRH mRNA
levels are unaffected by glucocorticoids at several extrahypothalamic
central nervous system sites (12, 13) and are paradoxically
up-regulated by glucocorticoids in cultured human placental
trophoblasts (14).
In vitro studies suggest that glucocorticoids inhibit CRH
gene transcription through specific sites within the CRH promoter
(15, 16, 17). Regulatory elements contained within the proximal 1 kb of the
CRH promoter are necessary and sufficient to confer cAMP-dependent
activation and glucocorticoid-dependent transcriptional regulation to
the stably transfected CRH gene (18) or to CRH promoter-reporter
constructs in transient transfection studies (15, 16, 17). The cAMP
response element (CRE, 5'-TGACGTCA-3') centered at -224
nucleotide (nt) affects basal promoter activity as well as
cAMP-dependent,
12-O-tetradecanoylphorbol-13-acetate-dependent,
and depolarization-dependent transcriptional activation of the CRH
promoter (19, 20, 21). In contrast, localization and characterization
of cis-acting elements mediating glucocorticoid-dependent
repression within the CRH promoter and potential mechanisms involved in
hormonal repression remain uncertain (22).
Glucocorticoid effects are mediated through specific, ligand-dependent
interactions with GR. After corticosteroid binding, GR influences
transcription through distinct mechanisms that can involve direct DNA
binding (23, 24) and/or protein-protein interactions (25, 26, 27). For
example, at the osteocalcin promoter GR binds a GRE that overlaps the
binding site for TATA box-binding protein, and GR-DNA binding reduces
transcription by preventing the binding of a basal transcription factor
(28, 29). Within the model of composite regulation, GR interacts with
other transcription factors at adjacent or overlapping
DNA-regulatory elements (30, 31). Several examples of composite
regulation between GR and AP-1 nucleoproteins (c-jun and
c-fos) have been observed (31, 32). In this setting, the
transcriptional effect of liganded GR may be influenced by
cell-specific factors as well as relative concentrations of
c-jun and c-fos (31). In addition, hormonal
repression may occur through mechanisms that do not require direct DNA
binding of GR at specific target genes, but rather involve soluble
interaction between GR and regulatory proteins such as AP-1 family
members or NF-
B (33, 34). In addition, GR interacts with several
functionally important coadaptors, including CREB-binding protein (CBP)
and GR-interacting protein (GRIP-1) (35, 36, 37).
In an effort to better understand potential mechanisms involved in
glucocorticoid-dependent repression of CRH, we have attempted to
specifically localize cis-acting region(s) of the CRH
promoter critical for hormonal repression. The mouse corticotroph
AtT-20 cell line is a useful in vitro model for repression
of CRH, since glucocorticoids repress transcription of the endogenous
POMC gene as well as exogenous CRH promoter introduced by either stable
or transient transfection. Using a series of CRH promoter-luciferase
constructs, we have previously reported that nested deletion of the CRH
promoter (from -278 to -249 nt) results in complete loss of
glucocorticoid-dependent repression of cAMP-stimulated CRH promoter
activity (15). Analysis of this highly conserved sequence between -278
and -249 nt demonstrated the presence of potential glucocorticoid and
AP-1 response element motifs, suggesting that direct DNA binding of
both GR and AP-1 nucleoproteins may play a role in regulation of CRH
promoter activity. Our objectives in the present series of studies were
1) to further localize the negative glucocorticoid response element
(nGRE); 2) to characterize protein-DNA interactions involving GR and
AP-1 nucleoproteins at this site; and 3) to assess the functional role
of putative GR and AP-1 binding sites within this element in the
context of both intact CRH and heterologous promoter constructs. Our
results establish that the nGRE plays an important role in hormonal
activation mediated by both cAMP and AP-1 nucleoproteins and also
mediates glucocorticoid-dependent repression. Further, promoter
mutations that interrupt either AP-1 or GR binding activity to the nGRE
lead to abrogation of glucocorticoid-dependent repression, suggesting
that interactions between GR and AP-1 or related nucleoproteins may
mediate hormonal repression at this regulatory element.
 |
RESULTS
|
---|
Nested Deletions of the hCRH Promoter Localize a nGRE between -278
and -249 nt
In previous studies, nested deletions to -278 nt retained
cAMP-dependent activation and dexamethasone (DEX)-dependent repression
while DEX-dependent repression was eliminated when CRH promoter
constructs were shortened to -249 nt (15). Additional CRH promoter
deletion constructs were used to confirm and further localize putative
nGRE site(s) mediating hormonal repression (Fig. 1
). As previously shown,
glucocorticoid-dependent repression was retained in constructs
containing sequences to -278 nt, while deletion to -249 nt completely
eliminated DEX-dependent repression. Two deletions that disrupt the
region between -278 and -249 nt [CRH(-270)luc and CRH(-260)luc]
retained partial glucocorticoid-dependent repression. As expected,
cAMP responsiveness was retained in all constructs containing the
cAMP-response element (CRE) at -224 nt (data not shown). Loss of
DEX-dependent repression with preservation of cAMP responsiveness
in both CRH(-249)luc and CRH(-235)luc indicates that glucocorticoids
do not repress CRH promoter activity through interference with the CRE
or CRE-binding proteins. This result is in contrast to the findings of
Guardiola-Diaz et al. (16) who reported colocalization of a
glucocorticoid-dependent repression to the CRE (see
Discussion).

View larger version (23K):
[in this window]
[in a new window]
|
Figure 1. Nested Deletions of the CRH Promoter Confirm the
Localization of the nGRE between -278 and -249 nt
AtT-20 cells were transfected with hCRH promoter-luciferase reporter
constructs by calcium phosphate precipitation as described in
Materials and Methods. Data (mean ±
SEM of at least three independent experiments) are
expressed as the percentage of 8-Br-cAMP-stimulated promoter activity
observed with 8-Br-cAMP and DEX cotreatment; therefore, no repression
is 100%. Nested deletions are designated by the most 5' nt of the hCRH
promoter retained. * Indicates significant DEX-dependent repression.
Indicates significantly less repression than CRH(-918)luc. Nested
deletion constructs containing an intact nGRE (constructs extending
upstream of -278 nt) demonstrated approximately a 2-fold DEX-dependent
repression of cAMP-stimulated promoter activity ( 50% of 8-Br-cAMP
stimulated). Nested deletions that eliminated the entire nGRE
(CRH(-249)luc, CRH(-235)luc, CRH(-200)luc) demonstrated no
DEX-dependent repression. Nested deletions that disrupted the nGRE
(CRH(-270)luc, CRH(-260)luc) demonstrated significant, but reduced,
glucocorticoid repression of cAMP-stimulated CRH promoter activity.
|
|
The region between -278 and -249 nt is highly conserved, with 100%
homology between rat, ovine, and human genes. Analysis of this sequence
identified three sites with GRE half-site homology (Fig. 2B
). In contrast to consensus GRE sites
that support GR dimer formation and are in palindromic orientation
(Fig. 2A
), the GRE half-sites of the CRH gene are organized as direct
or inverted repeats. In addition, two sites having homology with
consensus AP-1 response elements (Fig. 2C
) were identified within the
functionally defined nGRE (Fig. 2B
). For subsequent binding and
functional studies, putative GR binding sites 13 and putative AP-1
binding sites 1 and 2 refer to upstream and downstream elements
indicated in Fig. 2B
(see Materials and Methods).

View larger version (21K):
[in this window]
[in a new window]
|
Figure 2. Sequence and Putative Binding Sites in the Human
CRH Promoter nGRE (-278 to -249 nt)
This region of the hCRH promoter has 100% homology with rat and ovine
CRH genes. Sites with GRE half-site homology are shown on the
top (sense) strand and have either 4/6 (GR-sites 1 and
3) or 5/6 (GR-site 2) similarity with the GRE half-site consensus
(5'-TGTACA-3') sequence. Sites with AP-1 site homology are shown on the
bottom (antisense) strand; AP1-site 1 has 6/7 similarity
with the nonclassical AP-1 site of the composite GRE of the mouse
proliferin gene (30 ), while AP1-site 2 has 5/7 similarity with the
consensus AP-1 element (5'-TGACTCA-3'). For mutant probes used in EMSA
and mutant constructs used in transient transfection assays, putative
transcription factor binding sites were mutated to EcoRI
restriction sites (5'-GAATTC-3'). Specifically, GR binding site mutants
were designated mut1 to mut3 with respect to GR sites 13 shown in
panel B (e.g. mut2 indicates mutation of GR-site2).
Mutation of GR binding sites in functional constructs was similarly
designated (e.g. GRsite2 indicates mutation of
GR-site2).
|
|
Localization of GR Binding to the CRH nGRE
Ligand-bound GR can influence transcription by direct DNA binding
to regulatory sequences (28, 31, 38, 39) or through protein-protein
interactions involving GR and other transcription factors and/or
coadaptors (31, 33, 40, 41). To better define the role of GR-DNA
binding, we sought to characterize and localize high-affinity GR
interactions with the CRH nGRE sequence. Electrophoretic mobility shift
assays (EMSAs) were performed using bacterially expressed rat GR
DNA-binding domain (GR-DBD, kindly provided by L. Freedman,
Sloan-Kettering Institute, New York, NY) (42) and wild-type or mutant
CRH nGRE probe (Fig. 3
). As expected,
GR-DBD specifically bound a positive control probe containing the GRE
from the mouse mammary tumor virus (MMTV) at two sites and, as
previously described, interacted with the CRH nGRE probe (CRH, -278 to
-249 nt) at two sites (15). In contrast, GR-DBD failed to shift the
negative control CRE probe (CRH, -220 to -228 nt). GR-DBD bound MMTV
and CRH probes with similar affinities (see Table 1
);
however, at the same protein concentration (20 ng),
GR-DBD interacted with MMTV to yield a protein-DNA complex consistent
with dimeric binding, while GR-DBD interactions at the CRH nGRE
produced a complex consistent with predominantly monomeric GR-DBD
binding. Interestingly, at higher GR-DBD concentrations a second,
higher mol wt band appeared that is consistent with GR-DBD binding at
two sites within the CRH nGRE probe (15).
To determine which potential GRE half-sites participate in
high-affinity GR-DBD binding, we introduced mutations into upstream,
middle, or downstream GRE sequences (designated mut1, mut2, and mut 3,
respectively) and examined GR binding using EMSA (Fig. 3
, data
summarized in Table 1
). Mutation of the middle GRE to an
EcoRI site (Fig. 3
, mut2) resulted in a 10-fold reduction in
the affinity (kd) of GR-DBD for the probe and a
commensurate reduction in percentage of two-site GR-DBD binding. In
contrast, mutation of the upstream or downstream GR binding sites
(mut1, mut3) reduced kd by 2-fold and dimer
formation by 4-fold. This identifies the middle GR binding site as the
high-affinity GR binding site within the functionally defined nGRE.
These data are supported by studies of nGRE probes containing mutations
at two GR binding sites. Mutation of GR-sites 1 and 2 (mut1,2) markedly
reduced GR-DBD affinity for the nGRE, while a less dramatic reduction
in affinity was observed when the middle GR binding site was preserved
(mut1, 3). As expected, mutation of all three GR binding sites
(mut1,2,3) eliminated detectable GR-DBD binding. The high-affinity GR
binding site identified in these EMSA experiments corresponds to the
same region of the CRH promoter in which high-affinity GR binding was
identified by deoxyribonuclease I (DNase I) footprinting (16).
AP-1 Interactions within the CRH nGRE
EMSA was also used to evaluate binding of purified,
bacterially expressed AP-1 proteins at putative AP-1 sites within the
CRH nGRE. As shown in Fig. 4A
, probes
containing either the consensus AP-1 binding site of the collagenase
promoter (5'-TGACTCA-3') or the CRH nGRE interacted with AP-1 proteins
as jun:jun homodimers and jun:fos heterodimers. Mutation of the
upstream AP-1 binding site to an EcoRI site (AP1-mut1) had
little effect on AP-1 binding, while mutation of the downstream
putative AP-1 binding site (AP1-mut2), markedly reduced both jun:jun
and jun:fos binding in vitro. These findings indicate that
the downstream AP-1 element (Fig. 2
, AP1-site 2) represents the
high-affinity AP-1 binding site within the nGRE. AP-1 binding activity
was confirmed by cross-competition studies (data not shown). In these
studies, excess unlabeled CRH, colAP1, or AP1-mut1 probes effectively
competed for AP-1 binding to labeled CRH or colAP1 probes. In contrast,
excess unlabeled AP1-mut2 probe (CRH probe containing a mutated
downstream AP-1 site) failed to compete for AP-1 binding at either of
these probes. Interestingly, mutation of the upstream AP-1 site
(AP1-mut1) somewhat reduced GR-DBD binding to the CRH nGRE, while
mutation of the downstream AP1-site (AP1-mut2) did not (Fig. 4A
). Since
the AP1-mut1 mutation also disrupts the distal GRE half-site, decreased
GR-DBD dimer formation suggests that this half-site participates in
GR-DBD dimerization at the nGRE. That AP-1 binding was preserved with
mutation of the high-affinity GR binding site (Fig. 4B
) indicates that
GR and AP-1 binding activities can be experimentally distinguished
through selective mutation of binding sites.
Internal Deletions and Discrete Mutations within the Intact CRH
Promoter
Analysis of nested deletions may be complicated by the serial
removal of upstream sequences that influence defined regulatory
elements through additive or synergistic interactions. Thus, additional
transfection studies using constructs containing internal deletions or
discrete mutations of the nGRE (-278 to -249 nt) were performed to
further define the functional role of the nGRE within the context of
the intact CRH promoter (to -918 nt). As shown in Fig. 5
, internal deletion of the entire nGRE
(CRH(-918)[
278249]luc) significantly reduced, but did not
eliminate, DEX-dependent repression relative to the wild-type CRH
promoter. This confirms an important functional role for sequences
between -278 and -249 nt, but suggests that additional upstream sites
may participate in glucocorticoid-dependent repression. In an effort to
localize secondary glucocorticoid-responsive elements, we extended the
internal deletion to include additional 5'-regulatory sequences from
(CRH(-918)[
295249]luc and CRH(-918)[
340249]luc). Both
of these constructs retained partial glucocorticoid-dependent
repression that was not different from the more limited nGRE internal
deletion construct (CRH(-918) [
278249]luc). Thus, it appears
that CRH promoter sequences between -340 and -918 nt contribute to
glucocorticoid-dependent regulation in a manner independent of the nGRE
between -278 to -249 nt.
We also examined the effects of specific mutations of GR- and AP-1
binding sites within the context of the CRH promoter (Fig. 5
). Mutation
of all three GR binding sites (CRH(-918)[
GRsites1,2,3]luc)
reduced glucocorticoid-dependent repression by approximately 50%.
Similar reductions in glucocorticoid-dependent repression were seen
when only the high-affinity GR binding site was mutated
(CRH(-918)[
GRsite2]luc, which corresponds to the mut2 probe in
Fig. 3
). This confirms the functional importance of the
high-affinity GR binding site defined by EMSA. Interestingly,
mutation of the high-affinity AP-1 binding site (CRH(-918)[
AP1
site2]luc, which corresponds to the AP1-mut2 probe in Fig. 3
) also
decreased glucocorticoid-dependent repression relative to the wild-type
CRH promoter. Since this mutation does not interfere with GR-DBD
binding (Fig. 4A
), the decreased DEX-dependent repression associated
with this mutation suggests a specific role for AP-1 binding in
hormonal regulation.
The possibility of interactions between GR- and CRE-binding proteins or
their cognate coadaptors is also of interest, since GR is capable of
physical interactions with CREB (43) and can repress cAMP-stimulated
promoter activity through interference with mutually required cofactors
(40, 44). Furthermore, within the CRH promoter, Guardiola-Diaz et
al. localized glucocorticoid-dependent repression and cAMP
stimulation to the CRE (16). Experiments summarized in Fig. 6
specifically examine the regulatory
relationship between nGRE and CRE sequences within the CRH promoter. As
previously reported, internal deletion of the CRE
(CRH(-918)[
CRE]luc) significantly reduced cAMP-dependent
activation relative to the intact promoter but did not interfere with
hormonal repression (15). Similarly, internal deletion of the CRE in
the context of CRH(-249)luc also reduced cAMP activation relative to
the parent construct. Interestingly, internal deletion of the high
affinity AP-1 site (CRH(-918)[
A P1site2]luc) significantly
reduced cAMP responsiveness, suggesting either that the high-affinity
AP-1 site of the nGRE functions as a secondary CRE or that the AP-1 and
CRE interact synergistically. As expected, constructs lacking a defined
CRE, including CRH(-200)luc, CRH(-38)luc, and
hCG(-100)luc,
demonstrated only mild (
1.5 fold) nonspecific cAMP induction that
was not repressible by glucocorticoids.
The nGRE and CRE Confer Transcriptional Regulation to a
Heterologous Promoter
Many enhancer and repressor elements confer signal-dependent
regulation to a heterologous promoter. To examine regulation in a
heterologous context, defined regulatory elements were placed upstream
of the minimal Drosophila alcohol dehydrogenase (Adh)
promoter, and hormonal regulation of these constructs was examined in
transfected AtT-20 cells (Fig. 7
). The
basal Adh promoter demonstrated no hormonal regulation; however, CRH
promoter fragments that included both CRE and nGRE sequences
(CRH[-285 to -90])Adh and CRH[-285 to -160]Adh) conferred both
cAMP-dependent stimulation and DEX-dependent repression to the Adh
promoter. Studies of the CRE and nGRE in isolation confirm the
structural independence of these elements. One or three copies of the
CRE (1x CRH CRE-Adh and 3x CRH CRE-Adh) conferred cAMP-dependent
induction but not DEX-dependent repression to the Adh promoter. In
contrast, the nGRE (1x CRH nGRE-Adh and 3x CRH nGRE-Adh) conferred
mild cAMP responsiveness as well as glucocorticoid-dependent repression
to the Adh promoter, consistent with the function of this element as
both a nGRE and secondary CRE.
In addition, we examined cAMP and glucocorticoid effects on an
additional construct containing three copies of composite GRE from the
mouse proliferin promoter [3x PLF cGRE-Adh also called PLFG3.1
(31)]. This element contains both GR and AP-1 responsive elements
upstream of the heterologous Adh promoter. As indicated in Fig. 7
, the
PLF cGRE conferred both cAMP- and glucocorticoid-dependent regulation
to the Adh promoter. Thus, it appears that cAMP is capable of
stimulating transcriptional activation through AP-1 responsive elements
in the context of AtT-20 cells. It is unclear whether this effect is
mediated through changes in AP-1 nucleoprotein levels, phosphorylation
status, or through phosphorylation of nucleoproteins more classically
associated with protein kinase A (PKA)-dependent activation pathway,
such as CREB or ATF-1.
The nGRE and CRE Regulate Basal Promoter Activity
Many hormonally responsive elements influence the rate of basal
transcription. We observed that both the high-affinity AP-1 site within
the nGRE and the consensus CRE influenced basal CRH promoter activity
(Table 2
). Mutations that replaced the high-affinity
AP-1 or disrupted the CRE both decreased basal transcription,
suggesting that both of these elements influence transcription in the
absence of cAMP. This conclusion was supported by parallel experiments
using the heterologous Adh promoter. Relative to the minimal Adh
promoter, one or three copies of the CRE dramatically augmented basal
transcription. Similarly, one or three copies of the nGRE (-278 to
-249 nt) placed upstream of the heterologous Adh promoter produced a
3- to 6-fold increase in basal transcription. The cGRE from the
proliferin gene produced a similar increase in basal transcription.
The CRH nGRE Represents a Functional AP-1 Site
To assess the functionality of AP-1 sites identified by sequence
analysis and in vitro binding studies, we performed
transient expression studies in which relative levels of
c-jun and c-fos were manipulated by
cotransfection of AP-1 expression plasmids (Fig. 8
). Transfection of the c-jun
expression plasmid induced the transcriptional activity of the intact
CRH promoter by 9-fold. This induction was repressible by
glucocorticoids. In contrast, overexpression of c-fos
produced less dramatic induction of CRH that was minimally inhibited by
DEX. A different pattern of AP-1 activation and
glucocorticoid-dependent repression was obtained when the nGRE was
examined in the context of the heterologous Adh promoter. In this
context, c-fos produced a greater magnitude of induction
than c-jun (22-fold vs. 8-fold), and conditions
of jun or fos excess were both sensitive to DEX-dependent repression.
Two control plasmids were also evaluated. The composite element from
the proliferin gene was activated by both jun and fos, and DEX
effectively inhibited activation under conditions of c-jun
excess. In contrast, the CRE was minimally responsive to overexpressed
AP-1 proteins and was not DEX repressible under any conditions
tested.

View larger version (27K):
[in this window]
[in a new window]
|
Figure 8. The nGRE Responds to Overexpressed AP-1 Proteins
and Glucocorticoids Repress AP-1-Stimulated Activity of the CRH nGRE
AtT-20 cells were cotransfected with the indicated reporter (2
µg), expression vectors for c-jun or
c-fos (4 µg), and expression vector for GR (2
µg). Cells were then treated, harvested, and assayed as described in
Materials and Methods; data (mean ±
SEM of at least three independent experiments) are
expressed as fold induction. All constructs demonstrated significant
(P < 0.05) induction with overexpressed
c-jun or c-fos except 3x CRH CRE-Adh,
which did not induce with c-jun. Indicates
significant DEX-dependent repression of c-jun- or
c-fos-stimulated promoter activity.
|
|
Role of High-Affinity GR- and AP-1 Binding Sites in Stimulation and
Repression
High-affinity GR- and AP-1 binding sites were mutated to
EcoRI sites in the context of the 3x CRH nGRE-Adh construct
to specifically assess the role of these sites in cAMP-dependent
induction, AP-1 dependent induction, and DEX-dependent repression. As
shown in Fig. 9A
, mutation of either the high-affinity GR binding site
or the high-affinity AP-1 site significantly decreased the magnitude of
cAMP-dependent induction relative to the intact nGRE. In addition, both
mutations led to complete loss of glucocorticoid repression of
cAMP-stimulated activity. Stimulation by AP-1 proteins and
glucocorticoid repression of this activity were also examined using
these mutant constructs. As shown in Fig. 9B
, mutation of high-affinity
GR or AP-1 sites had no effect on c-jun-mediated induction
but decreased c-fos-mediated induction. Interestingly,
glucocorticoid-dependent repression of AP-1-stimulated activity was
preserved, suggesting that, at this element, repression of both cAMP
activation and AP-1 activation is mediated through distinct
mechanisms.

View larger version (37K):
[in this window]
[in a new window]
|
Figure 9. Mutation of High-Affinity GR or AP-1 Binding Sites
Reduces cAMP Stimulation, DEX-Dependent Repression, and
c-fos Stimulation of the CRH nGRE
AtT-20 cells were transfected and treated as described in
Materials and Methods (panel A) or Fig. 8 (panel B).
Data (mean ± SEM of at least three independent
experiments) are expressed as fold induction. * Indicates DEX-dependent
repression. Indicates reduced activation or repression
vs. 3x CRH nGRE-Adh.
|
|
CREB Interactions at the CRH nGRE
AP-1 elements can mediate induction by CREB family members (45, 46), and cAMP modestly activates the CRH nGRE (Fig. 9A
). Thus, we studied the role of CREB at the CRH nGRE
in using cotransfection of plasmids that express either full-length
CREB (CREB-FL) or a dominant negative truncated CREB (CREB-BR) capable
of binding DNA but lacking the transactivation domain (47). As shown in
Fig. 10A
, CRH nGRE and CRH CRE were
induced by 8-Br-cAMP, and this induction was reduced by cotransfection
of CREB-BR. Furthermore, overexpression of full-length CREB stimulated
activity at each of these elements in a non-cAMP-dependent manner (Fig. 10A
). The nGRE was unexpectedly more sensitive to overexpressed CREB
(
40-fold induction) than classical CRE (
5-fold induction,
P < 0.05). This stimulation appears to be mediated by
the high-affinity AP-1 site, since mutation of this site (3x CRH nGRE
AP-1 site 2) abrogated stimulation by both cAMP and CREB.
Transcriptional activation mediated by CREB and cAMP was clearly due to
enhancer elements contained within the nGRE, as no stimulation was
observed at the basal Adh promoter. Interestingly, CREB-stimulated
activity at the CRH nGRE or CRH CRE was not repressed by
glucocorticoids (Fig. 10B
).
 |
DISCUSSION
|
---|
While intracellular signaling events leading to activation of gene
transcription by glucocorticoids are relatively well understood, many
important biological effects of corticosteroids are mediated through
repression of specific gene transcription and involve complex, distinct
mechanisms of transcriptional regulation that are cell- and
promoter-specific (48). The CRH gene is of particular interest as a
model for glucocorticoid-dependent repression, since it is a
physiologically relevant target of corticosteroids and a critical
component of long-loop feedback regulation of the HPA axis (3, 22).
Although the corticotroph-derived AtT-20 cell line used in this series
of transient transfection experiments is not a site of endogenous CRH
expression (49), it represents a parallel limb of physiological
corticosteroid feedback regulation and has been used in several
independent laboratories to investigate
glucocorticoid-dependent repression of CRH.
The present study accomplishes the following: 1) a
cis-acting site of the CRH promoter that mediates negative
regulation by glucocorticoids was precisely localized; 2) the
functional role of this element was defined in the context of both
intact CRH and heterologous Adh promoters; 3) the sites and affinities
of GR and AP-1 binding within the functionally defined nGRE were
determined; and 4) the nGRE was established as a site that can mediate
transcriptional activation by both cAMP and AP-1 proteins as well as
transcriptional repression by glucocorticoids. Together these results
suggest that glucocorticoids inhibit CRH gene transcription through a
mechanism that involves direct binding of GR, as well as AP-1 or
related nucleoproteins, to be defined cis-acting element of
the CRH promoter.
Although the proximal 1 kb of the CRH promoter confers
glucocorticoid-dependent regulation to various reporter genes (16, 50),
the localization of cis-acting elements within the CRH
promoter and potential mechanism of glucocorticoid-dependent
repression remain uncertain. Sequence analysis demonstrates remarkable
conservation between species within the proximal promoter of the CRH
gene (>90% between rat, ovine, and human genes between -300 and +1),
suggesting an important role for functional elements contained within
this region. Although no classical consensus GRE sequences have been
identified within the CRH promoter, Guardiola-Diaz et al.
demonstrated several regions of high-affinity GR binding using rat GR
DNA-binding domain in a DNase I protection assay (16). Indeed, the
functional nGRE localized in our study corresponds precisely to one of
these sites. Interestingly, Guardiola-Diaz et al. observed
that glucocorticoid-dependent repression was maintained in the plasmid
CRH(-249)CAT (16), while we observed loss of repression in an
equivalent luciferase-based construct (CRH(-249)luc, see Fig. 6
). In
addition, Guardiola-Diaz et al. reported suppression of
heterologous construct containing the CRE linked to an SV40 promoter
(16). In contrast, we observed no repression when the CRE was linked to
a heterologous Adh promoter and both cAMP-dependent induction and
glucocorticoid-dependent repression when the nGRE (-278 to -249) was
placed upstream of this same promoter (Fig. 7
).
The experimental basis for these disparate results is uncertain.
Results obtained in the present study, including evaluation of the nGRE
through additional nested and internal deletion constructs as well as
heterologous contexts, clearly establish the localization and
reproducibility of the nGRE under experimental conditions used in our
laboratory. A possible explanation for these different results may be
related to the presence of a cryptic AP-1 site in the puc18 plasmid
backbone used in the aforementioned study (16), which is absent in the
pBR-based backbone used in the present series of experiments. The
potential for artifactual glucocorticoid repression in the
pUC18-derived plasmid containing enhancer elements has been
previously reported (51) and would explain the apparent glucocorticoid
repression observed in CRH or heterologous promoter constructs
containing the CRE reported by Guardiola-Diaz et al. (16).
However, unpublished data indicate a similar pattern of
glucocorticoid-dependent repression is observed for these constructs
when the cryptic AP-1 site is deleted (S. Coon and A. Seasholtz,
personal communication). An alternative possibility is that differences
in the host AtT-20 cell line may account for different regulatory
effects. Since CRH is not expressed in the corticotroph and its
regulation in AtT-20 cells is of interest primarily as a model system,
mechanisms of glucocorticoid-dependent repression defined by the
Seasholtz laboratory (16) and in the present experiments are both of
heuristic interest. Clearly, it will be important to determine which
potential cis-acting element(s) and mechanisms defined by
in vitro studies of the CRH promoter are critical in
glucocorticoid repression of hypothalamic CRH expression in
situ.
Our observation that internal deletion of the nGRE in the context of
the intact CRH promoter partially reduced glucocorticoid-dependent
repression suggests that upstream sequences within the CRH promoter
also contribute to transcriptional repression. Glucocorticoid
repression in constructs containing internal deletions of the nGRE and
surrounding sequences is specific, since neither constitutive nor
cAMP-responsive control promoters demonstrate DEX-dependent
repression. In an effort to localize potential regions of the CRH
promoter that contribute to hormonal repression independent of the
nGRE, we extended the internal deletion nGRE to include additional
upstream sequences. However, both CRH
(-295/-249) and
CRH
(-340/-249) demonstrated a magnitude of DEX-dependent
repression comparable to the more limited nGRE deletion
(CRH
(-278/-249)). These results suggest that a previously
identified GR binding site between -313 and -301 (16) does not
represent a functional nGRE, and that additional hormonally responsive
element(s) are located upstream of -340 nt.
Mechanisms of glucocorticoid-mediated repression can be broadly divided
into those that require direct GR binding to the target gene promoter
(e.g. occlusion, composite regulation) and those that act
without DNA binding (e.g. soluble interactions,
cross-repression, squelching). Our gel-shift results demonstrating
high-affinity GR binding at the middle GRE half-site confirm the DNase
I protection results of Guardiola-Diaz et al. (16). A
mechanism of glucocorticoid-dependent repression that requires direct
DNA binding is supported by the observation that mutations that disrupt
GR binding activity at this site reduce hormonal repression (Fig. 5
).
This is consistent with previous studies of Majzoub and co-workers
(50), who observed that GR mutants lacking DNA-binding activity fail to
repress CRH gene expression.
GR typically interacts as a dimer at "simple" or activating GREs
(52). Within negatively regulated promoters, dimeric GR binding has
been observed at the proliferin composite GRE (31), while trimeric
GR-DNA interactions have been observed at the POMC gene (38). Within
the CRH nGRE, the high-affinity GRE half-site is flanked by two lower
affinity GRE half-sites, suggesting that GR interacts as a dimer or
trimer at this site. However, the classic palindromic GRE organization
that supports dimeric GR binding is not present within the CRH nGRE
(Fig. 2
). At higher concentrations of GR-DBD, we have observed GR-DNA
interactions at the lower affinity GRE half-sites (15). However,
because our studies used the DNA-binding domain rather than full-length
GR, it is unclear whether this element would support homodimeric
binding of full-length GR.
Several examples of glucocorticoid-dependent regulation involve
interactions between GR and members of the basic leucine zipper
superfamily (e.g. AP-1 and CREB/ATF family members (31, 40, 53). Our results establish that the proximal AP-1 sequence within the
CRH nGRE is capable of specific and high-affinity interactions with
both jun:jun homo- and jun:fos heterodimers. Furthermore, the
functional activity mediated through the proximal AP-1 element in
response to both cAMP and overexpressed AP-1 proteins establish that
AP-1 binding activity is associated with transcriptional activation.
The magnitude of transcriptional activation produced by overexpression
of c-jun and c-fos, respectively, differed
between intact CRH and minimal heterologous promoters. This may be
related to the presence of other functional AP-1-responsive elements
within the CRH promoter (54) or to endogenous expression of AP-1 family
members within AtT-20 corticotrophs.
In addition to mediating activation in response to overexpressed AP-1
nucleoproteins, we found that the nGRE functions as a cAMP-response
element independent of the CRE at -224 nt. When examined in a
heterologous context, the consensus CRE increased both basal and
cAMP-stimulated transcription more than the nGRE. However, within the
context of the intact CRH promoter, internal deletion of either element
produced a similar decrement in cAMP response. The mechanism of
cAMP-dependent activation through the nGRE is uncertain. One
possibility is that cAMP acts through a classical PKA-dependent pathway
to stimulate phosphorylation of CREB, ATF-1, or related nucleoproteins.
CREB and related nucleoproteins are capable of binding some AP-1
response elements and may lead to either transcriptional activation or
repression in a cell- and promoter-specific fashion (45, 55, 56).
In addition, CREB/ATF and AP-1 family members may heterodimerize at
certain CRE and/or AP-1 elements (55, 57, 58). The ability of a
dominant negative CREB mutant that lacks the transcriptional activation
domain but retains DNA-binding activity to suppress the cAMP response
mediated through the nGRE suggests that CREB is capable of interacting
at the CRH nGRE. Another possibility is that cAMP acts through
PKA-dependent transcriptional effects leading to changes in the
absolute or relative concentrations of c-jun or
c-fos. Another hypothesis is that synergy exists between
nucleoproteins interacting at nGRE (AP-1) and CRE sites. In this model,
synergistic nucleoprotein interactions could contribute to
cAMP-dependent activation mediated through the nGRE, and liganded GR
could disrupt these interactions to produce glucocorticoid-dependent
repression. Alternatively, PKA stimulation may influence other signal
transduction elements, like mitogen/stress-activated kinases
that regulate phosphorylation-dependent activation of CREB, as well
as activation of AP-1 response elements in several neuronal
and endocrine cell types (59, 60, 61, 62).
The localization of GR and AP-1 binding within a single regulatory
element, coupled with the loss of hormonal repression observed after
mutation of either site, suggests that the CRH nGRE functions as a
composite regulatory element. This conclusion is supported by the
observation that hormonal regulation of the CRH nGRE parallels that of
the well characterized composite element from the mouse proliferin
gene. In addition, the CRH nGRE has a complex structure similar to that
of the previously described composite GREs from the mouse proliferin
and bovine PRL genes (31, 63). The mechanism by which GR and AP-1
nucleoproteins interact at composite elements to activate or repress
gene transcription in a tissue-specific fashion remains uncertain.
While we did not examine co-occupancy of GR and AP-1 nucleoproteins
at the nGRE, it is possible that GR binding may interfere with AP-1
binding or influence the composition of AP-1 nucleoproteins at this
element. In addition, the role of coadaptors in mediating regulatory
responses from composite elements has yet to be defined. One
interesting possibility is that the host of transcription factors
recruited to a composite element then determines the composition of the
coadaptor complex and hence the signal transmitted to the basal
transcription apparatus. Within this model, the ability of
glucocorticoids to effect positive and negative regulation from a
composite response element may be mediated through differential
recruitment of coadaptors that facilitate regional histone acetylation
and deacetylation. The cell specificity observed for directional
regulation of composite glucocorticoid response elements may be
influenced not only by relative concentrations and phosphorylation
status of AP-1 and related nucleoproteins, but also the host cell
repertoire of coactivator and corepressor proteins. In any case, it
will be crucial to extend the current findings related to
glucocorticoid-dependent relation of the CRH promoter to other in
vitro and in vivo models to better understand the
molecular mechanisms of negative glucocorticoid feedback of the HPA
axis.
 |
MATERIALS AND METHODS
|
---|
EMSA
EMSA was performed as previously described (15, 64). Briefly,
DNA probes were created by annealing complementary oligonucleotides
designed with 5'-overhangs, labeled using the Klenow fragment of DNA
polymerase, dNTPs, and [32P](
)dATP, and purified by
chromatography over G50 Sephadex (Pharmacia Biotech,
Uppsala, Sweden) and phenol-chloroform extraction. Probes with the
following target sequences were prepared (consensus sequences shown in
bold): MMTV GRE, containing the palindromic consensus GRE
from mouse mammary tumor virus (sense,
5'-GTTGGGTTACAAACTGTTCT-3'; antisense,
5-'TGGTTAGAACAGTTTGTAAC-3'); CRE, containing the
8-bp CRE present in the hCRH promoter at -224 nt (sense,
5'-GTTGGTGACGTCA-3'; antisense,
5'-TGGTTTGACGTCA-3'); CRH, containing the nGRE from hCRH
(-278 to -249 nt) (sense, 5'-ATTTTTGTCAATGGACAAGTCATA-3'; antisense,
5'-TT-CTTATGACTTGTCCATTGACA-3'); colAP1, containing the consensus
AP-1 binding site from the collagenase promoter (-73 to -66 nt)
(sense, 5'-GTTGGTGAGTCA-3'; antisense,
5'-GGTTGTGACTCA -3').
In addition, CRH nGRE (-278 to -249 nt) probes were created in which
potential GR binding sites (Fig. 2B
, GR-sites 13) or potential
AP-1-binding sites (Fig. 2B
, AP1-sites 1 and 2) were mutated to
EcoRI restriction sites (5'-GAATTC-3'). GR binding site
mutants designated mut1 to mut3 refer to putative GR binding sites 13
enumerated in Fig. 2B
. AP-1 binding site mutants (AP1 mut1 and AP1
mut2) are designated with respect to putative AP-1 binding sites
illustrated in Fig. 2B
. The following mutant CRH probes were prepared
(mutated bases shown in bold): MUT 1, mutation of GR-site 1
(sense, 5'-ATGAATTCCAATGGACAAGTCATA-3'; antisense,
5'-TTCTTATGACTTGTCCATTGGAA-3'); MUT 2, mutation of
GR-site 2 (sense, 5'-ATTTTTGTCAAGAATTCAGTCATA-3';
antisense, 5'-TTCTTATGACTGAATTCTTGACA-3'); MUT 3,
mutation of GR-site 3 (sense,
5'-ATTTTT-GTCAATGGACAAGTCGAA-3'; antisense,
5'-TGAATTCG-ACTTGTCCATTGACA-3'); MUT 1,2, mutation of
GR-sites 1 and 2 (sense,
5'-ATGAATTCCAAGAATTCAGTCATA-3'; antisense,
5'-TTCTTATGACTGAATTCTTGGAA-3'); MUT 1,3, mutation
of GR-sites 1 and 3 (sense,
5'-ATGAATTCCAATGGACAAGTCGAA-3'; antisense,
5'-TGAATTCGACTTGTCCATTGGAA-3'); MUT 1,2,3,
mutation of GR-sites 13 (sense,
5'-ATGAATTCCAAGAATTCAGTCGAA-3';
antisense,
5'-TGAATTCGACTGAATTCTTGGAA-3');
AP1-MUT1, mutation of AP1-site 1 (sense,
5'-ATTTGAATTCTTGTCAATGGACAAGTCATA-3'; antisense,
5'-TTCTTATGACTTGTCCATGAATC-3'); AP1-MUT2, mutation of
AP1-site 2 (sense, 5'-ATTTTTGTCAATGGACGAATTCTA-3';
antisense, 5'-TTCT-TAGAATTCGTCCATTGACA-3').
Note that in AP-1 mutants, since a 6-bp EcoRI site
replaced a 7-bp AP1 site, the 5'-base of each AP-1 site (shown in
italics on the sense strand) was not altered. Radiolabeled
probe (
0.2 ng) was incubated with 020 ng purified rat GR-DNA
binding domain (GR-DBD, amino acids 440525, kindly provided by L.
Freedman, Sloan-Kettering Institute, New York, NY) or 020 ng AP-1
proteins (c-jun and c-fos, kindly provided by K.
Yamamoto, University of California, San Francisco, CA) in 10 µl
binding buffer (20 mM Tris-HCl, pH 7.9, 1 mM
EDTA, 1 mM DTT, 0.1% NP-40, 10% glycerol, 1 µg poly
dIC) for 15 min at room temperature. Bound and unbound species
were separated by either 10% nondenaturing PAGE for reactions
containing GR-DBD or 6% nondenaturing PAGE for reactions containing
AP-1 proteins. Autoradiograms were visualized using a PhosphorImager
(Molecular Dynamics, Inc., Sunnyvale, CA); free
and shifted probes were quantitated using ImageQuant software
(Molecular Dynamics, Inc.). Binding curves for nGRE probes
were created using a constant amount of probe and varying the amount of
protein (GR-DBD) added to each reaction. Affinity (kd) was
calculated using the method described by Freedman and Alroy (64), which
is summarized in the following equation:
 |
Plasmid Constructs
CRH(-918)luc, CRH(-664)luc, CRH(-364)luc,
CRH(-295)luc, CRH(-278)luc, CRH(-249)luc, and
CRH(-918)[
CRE]luc have been previously described (15).
CRH(-270)luc, CRH(-260)luc, CRH(-235)luc, and CRH(-200)luc were
prepared by PCR of CRH(-918)luc template using 30 mer sense primers
complementary to the corresponding sites of the hCRH gene containing
5'-HindIII tails and an antisense primer to the 5'-region of
luciferase (PGL2, Promega Corp., Madison, WI,
5'-CTTTATGTTTTTGGCGTCTTCCA-3'). After transitional subcloning into TA
cloning vector (Invitrogen, Carlsbad, CA), the PCR product
was digested with HindIII and ligated into
HindIII-digested pA3luc luciferase vector (65). CRH(-38)luc
was prepared by ligation of the HindIII fragment of
CRH(-918)luc (CRH, -918 to +38 nt) into the HindIII site
of the PxpI luciferase vector [ATCC, Manassas,
VA (66)], which was then digested with SalI and religated.
CRH(-918)[
-340 to -249]luc, CRH(-918)[
-295 to
-249]luc, and CRH(-918)[
-278 to -249]luc were generated by
recombinant PCR of CRH(-918)luc template. The upstream fragment was
generated using a sense primer to the pA3luc backbone (pA3luc sense,
5'-CTGGATCCCCGGGTACC-3') and an antisense primer complementary to the
region 5' of the desired deletion and containing a 5'-tail
complementary to the region directly 3' of the desired deletion. The
downstream fragment was generated using the PGL2 antisense primer and a
sense primer complementary to the region 3' of the desired deletion and
containing a 5' tail complementary to the region 5' of the desired
deletion. After gel purification, first-round PCR products were
denatured, allowed to anneal to each other, and then subjected to a
second round of PCR using the outside primers (PGL2 and pA3luc sense).
After transitional subcloning into TA cloning vector
(Invitrogen, San Diego, CA), the recombinant
HindIII fragment was ligated into
HindIII-digested pA3luc. CRH(-918)[
AP1-site 2],
CRH(-918)[
GR-site 2], and CRH(-918)[
GR-sites 1,2,3], in which
the indicated site(s) were replaced with EcoRI site(s) (see
Fig. 2B
), were generated by recombinant PCR as described above, but
with CRH-specific primers containing the desired mutations.
CRH(-918)[
GR-site 2], CRH(-918)[
GR-sites 1,2,3], and
CRH(-918)[
AP1-site 2] correspond to mut2, mut1,2,3, and AP1
mut2 probes used in EMSA experiments. CRH-(-249)[
CRE]luc was
created by digestion of CRH(-918)-[
CRE]luc with
SmaI and HindIII and ligation of this product
into SmaI/HindIII-digested pA3luc. All plasmid
constructs were confirmed by Sanger sequencing using the Sequenase
2.0 kit (United States Biochemical Corp., Cleveland,
OH).
HCG(-100)luc (67) and expression vector for full-length CRE binding
protein (CREB-FL, amino acids 1327) were kindly provided by J.
Hoeffler (Invitrogen). CREB-FL was placed under the
control of the CMV promoter by ligation of the
HindIII/XbaI fragment of CREB-FL into
HindIII/XbaI-digested CMV4 vector (kindly
provided by J. Omdahl, Department of Biochemistry and Molecular
Biology, University of New Mexico Health Science Center). CMV-driven
CREB-binding region (CREB-BR, amino acids 254327) was created by
BglII digestion of CMV-CREB-FL and religation of the
digested product (47). GR expression vector, pRSVhGR
(68), was
kindly provided by R. Evans (Salk Institute, La Jolla, CA). Expression
vectors for c-jun and c-fos were kindly provided
by R. Tijan (University of California, Berkley, CA). p
ODLO
(luciferase vector driven by a minimal Drosophila Adh
promoter (-33 to +53 nt) and PLFG3.1 (containing three copies of the
composite GRE from the proliferin promoter in p
ODLO(31)) were kindly
provided by K. Yamamoto (University of California, San Francisco, CA).
Regulatory elements were inserted upstream of the minimal Adh promoter
into PstI/SalI-digested p
ODLO using annealed
pairs of com-plementary oligonucleotides designed to have
PstI/SalI overhangs.
The following plasmids were created: [1x nGRE]Adh, containing the
nGRE of hCRH (-278 to -249 nt); [2x nGRE]Adh, containing two
copies of the nGRE of hCRH separated by a XhoI site; [1x
CRE]Adh, containing the CRE of hCRH (-231 to -217 nt); [3x
CRE]Adh, containing three copies of the CRE of hCRH; [3x
colAP1]Adh, containing three copies of the AP1 site of the collagenase
promoter (-77 to -62 nt); [1x nGRE-
GR site 2]Adh, containing
the nGRE of hCRH in which the middle GR binding site has been mutated
to an EcoRI site; [1x nGRE-
AP1 site 2], containing the
nGRE of hCRH in which the downstream AP-1 site has been mutated to an
EcoRI site.
[3x nGRE]Adh, containing three copies of the nGRE of hCRH, was
created by inserting an annealed oligonucleotide pair containing the
nGRE of hCRH with XhoI overhangs into the XhoI
site of [2x nGRE]Adh. [3x nGRE-
GR site 2]Adh and [3x
nGRE-
AP1 site 2] were created by inserting an oligonucleotide pair
containing two copies of the appropriate nGRE mutant with
PstI/XhoI overhangs into the PstI and
(engineered) XhoI sites of the 1x parent construct.
[CRH(-285 to -90)]Adh and [CRH(-285 to -160)]Adh were generated
by PCR of CRH(-918)luc template with 30 mer primers complementary to
the appropriate regions of the CRH gene. The sense primer contained a
5'-PstI tail and the antisense primer contained a
5'-SalI tail. PCR-generated fragments were digested with
PstI/SalI and inserted into
PstI/SalI-digested p
ODLO.
Cell Culture, Transfection, and Luciferase Assay
AtT-20 cells were maintained and transfected as previously
described (22). Briefly, AtT-20 cells were maintained under standard
conditions in DMEM containing 10% FBS. Cells were transfected with
CsCl2 purified DNA at 7080% confluence by
calcium-phosphate precipitation with glycerol shock. Each 60-mm plate
received 16 µg DNA, consisting of 25 µg luciferase reporter, 02
µg GR expression vector, 04 µg of expression vector for
c-jun, c-fos, CMV-CREB-FL, or CMV-CREB-BR, and
Bluescript KS+ carrier to 16 µg.
Statistical Analysis
Data are expressed as fold induction over a baseline level of
1.0 or as percentage of 8-Br-cAMP-stimulated promoter activity. Each
experimental condition in all transfection experiments was performed in
duplicate. The full-length CRH promoter construct (CRH[-918]luc) was
included in each independent experiment as a positive control for cAMP
induction and glucocorticoid repression. Pooled data represent the
mean ± SEM of at least three independent experiments.
The number of independent experiments for plasmid CRH(-918)luc was 76;
for other constructs the number of experiments ranged from 3 to 20.
Overall statistical analysis was performed using repeated-measures
ANOVA with post-hoc pairwise comparison. Statistical significance of
induction by 8-Br-cAMP, AP-1 proteins, or CREB-FL, and repression by
DEX, was determined by paired Students t test. Differences
in hormonal responses between different reporter/receptor combinations
were assessed by unpaired Students t test.
P < 0.05 was considered to be statistically
significant.
 |
ACKNOWLEDGMENTS
|
---|
The authors gratefully acknowledge the technical support of
Kathy Kilpatrick and the thoughtful review of this work by Drs. J.
Omdahl, T. Williams, and T. Graham.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Richard I. Dorin, M.D., Chief, Endocrinology and Metabolism, Albuquerque Veterans Administration Medical Center, Medical Service (111), 1501 San Pedro Drive SE, Albuquerque, New Mexico 87108.
This research was supported by Veterans Administration Research
Service.
Received for publication March 2, 1999.
Revision received May 20, 1999.
Accepted for publication June 23, 1999.
 |
REFERENCES
|
---|
-
Harbuz MS, Lightman SL 1989 Responses of hypothalamic and
pituitary mRNA to physical and psychological stress in the rat. J
Endocrinol 122:705711[Abstract]
-
Lightman SL, Harbuz MS, Knight RA, Chowdrey HS 1993 CRF mRNA
in normal and stress conditions. Ann NY Acad Sci 697:2838[Medline]
-
Muglia L, Jacobson L, Dikkes P, Majzoub JA 1995 Corticotropin-releasing hormone deficiency reveals major fetal but
not adult glucocorticoid need. Nature 373:427432[CrossRef][Medline]
-
Majzoub JA, Muglia LJ, Martinez C, Jacobson L 1995 Molecular
and transgenic studies of the corticotropin-releasing hormone gene. Ann
NY Acad Sci 771:293300[Medline]
-
Gomez MT, Magiakou MA, Mastorakos G, Chrousos GP 1993 The
pituitary corticotroph is not the rate limiting step in the
postoperative recovery of the hypothalamic-pituitary-adrenal axis in
patients with Cushing syndrome. J Clin Endocrinol Metab 77:173177[Abstract]
-
Kovacs KJ, Mezey E 1987 Dexamethasone inhibits
corticotropin-releasing factor gene expression in the rat
paraventricular nucleus. Neuroendocrinology 46:365368[Medline]
-
Kovacs K, Kiss JZ, Makara GB 1986 Glucocorticoid implants
around the hypothalamic paraventricular nucleus prevent the increase of
corticotropin-releasing factor and arginine vasopressin immunostaining
induced by adrenalectomy. Neuroendocrinology 44:229234[Medline]
-
Agnati LF, Fuxe K, Yu ZY, Harfstrand A, Okret S, Wikstrom AC,
Goldstein M, Zoli M, Vale W, Gustafsson JA 1985 Morphometrical analysis
of the distribution of corticotrophin releasing factor, glucocorticoid
receptor and phenylethanolamine-N-methyltransferase immunoreactive
structures in the paraventricular hypothalamic nucleus of the rat.
Neurosci Lett 54:147152[Medline]
-
Alexis MN, Kitraki E, Spanou K, Stylianopoulou F, Sekeris CE 1990 Ontogeny of the glucocorticoid receptor in the rat brain. Adv Exp
Med Biol 265:269276[Medline]
-
Whitfield Jr HJ, Brady LS, Smith MA, Mamalaki E, Fox RJ,
Herkenham M 1990 Optimization of cRNA probe in situ hybridization
methodology for localization of glucocorticoid receptor mRNA in rat
brain: a detailed protocol. Cell Mol Neurobiol 10:145157[Medline]
-
Herman JP, Schafer MK, Thompson RC, Watson SJ 1992 Rapid
regulation of corticotropin-releasing hormone gene transcription
in vivo. Mol Endocrinol 6:10611069[Abstract]
-
Imaki T, Nahan JL, Rivier C, Sawchenko PE, Vale W 1991 Differential regulation of corticotropin-releasing factor mRNA in rat
brain regions by glucocorticoids and stress. J Neurosci 11:585599[Abstract]
-
Frim DM, Robinson BG, Pasieka KB, Majzoub JA 1990 Differential
regulation of corticotropin-releasing hormone mRNA in rat brain.
Am J Physiol 258:E686692
-
Robinson BG, Emanuel RL, Frim DM, Majzoub JA 1988 Glucocorticoid stimulates expression of corticotropin-releasing hormone
gene in human placenta. Proc Natl Acad Sci USA 85:52445248[Abstract]
-
Malkoski SM, Handanos CM, Dorin RI 1997 Localization of a
negative glucocorticoid response element of the human corticotropin
releasing hormone gene. Mol Cell Endocrinol 127:189199[CrossRef][Medline]
-
Guardiola-Diaz HB, Kolinske JS, Gates LH, Seasholtz AF 1996 Negative glucocorticoid regulation of cyclic adenosine
3',5'-monophosphate-stimulated corticotropin-releasing
hormone-reporter expression in AtT-20 cells. Mol Endocrinol 10:317329[Abstract]
-
Van LP, Spengler DH, Holsboer F 1990 Glucocorticoid repression
of 3',5'-cyclic-adenosine monophosphate-dependent human
corticotropin-releasing-hormone gene promoter activity in a transfected
mouse anterior pituitary cell line. Endocrinology 127:14121418[Abstract]
-
Adler GK, Smas CM, Majzoub JA 1988 Expression and
dexamethasone regulation of the human corticotropin-releasing
hormone gene in a mouse anterior pituitary cell line. J Biol Chem 263:58465852[Abstract/Free Full Text]
-
Spengler D, Rupprecht R, Van LP, Holsboer F 1992 Identification and characterization of a 3',5'-cyclic adenosine
monophosphate-responsive element in the human corticotropin-releasing
hormone gene promoter. Mol Endocrinol 6:19311941[Abstract]
-
Mugele K, Kugler H, Spiess J 1993 Immortalization of a fetal
rat brain cell line that expresses corticotropin-releasing factor
mRNA. DNA Cell Biol 12:119126[Medline]
-
Guardiola-Diaz HM, Boswell C, Seasholtz AF 1994 The
cAMP-responsive element in the corticotropin-releasing hormone gene
mediates transcriptional regulation by depolarization. J Biol Chem 269:1478414791[Abstract/Free Full Text]
-
Vamvakopoulos NC, Chrousos GP 1993 Structural organization of
the 5' flanking region of the human corticotropin releasing hormone
gene. DNA Sequence 4:197206[Medline]
-
Dahlman-Wright K, Wright A, Carlstedt-Duke J, Gustafsson JA 1992 DNA-binding by the glucocorticoid receptor: a structural and
functional analysis. J Steroid Biochem Mol Biol 41:249272[CrossRef][Medline]
-
Zilliacus J, Wright AP, Carlstedt-Duke J, Gustafsson JA 1995 Structural determinants of DNA-binding specificity by steroid
receptors. Mol Endocrinol 9:389400[Medline]
-
Chen H, Srinivasan G, Thompson EB 1997 Protein-protein
interactions are implied in glucocorticoid receptor mutant
465*-mediated cell death. J Biol Chem 272:2587325880[Abstract/Free Full Text]
-
Wissink S, van Heerde EC, Schmitz ML, Kalkhoven E, van der
Burg B, Baeuerle PA, van der Saag PT 1997 Distinct domains of the RelA
NF-kappaB subunit are required for negative cross-talk and direct
interaction with the glucocorticoid receptor. J Biol Chem 272:2227822284[Abstract/Free Full Text]
-
Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin Jr
AS 1995 Characterization of mechanisms involved in transrepression of
NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 15:943953[Abstract]
-
Stromstedt PE, Poellinger L, Gustafsson JA, Carlstedt-Duke J 1991 The glucocorticoid receptor binds to a sequence overlapping the
TATA box of the human osteocalcin promoter: a potential mechanism for
negative regulation. Mol Cell Biol 11:33793383[Medline]
-
Ray A, LaForge KS, Sehgal PB 1990 On the mechanism for
efficient repression of the interleukin-6 promoter by glucocorticoids:
enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell
Biol 10:57365746[Medline]
-
Hoeppner MA, Mordacq JC, Linzer DI 1995 Role of the composite
glucocorticoid response element in proliferin gene expression. Gene
Expression 5:133141[Medline]
-
Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR 1990 Transcription factor interactions: selectors of positive or negative
regulation from a single DNA element. Science 249:12661272[Medline]
-
Zhang XK, Dong JM, Chiu JF 1991 Regulation of
-fetoprotein gene expression by antagonism between AP-1 and the
glucocorticoid receptor at their overlapping binding site. J Biol
Chem 266:82488254[Abstract/Free Full Text]
-
Liden J, Delaunay F, Rafter I, Gustafsson J, Okret S 1997 A
new function for the C-terminal zinc finger of the glucocorticoid
receptor. Repression of RelA transactivation. J Biol Chem 272:2146721472[Abstract/Free Full Text]
-
Caldenhoven E, Liden J, Wissink S, Van de Stolpe A,
Raaijmakers J, Koenderman L, Okret S, Gustafsson JA, van der Saag PT 1995 Negative cross-talk between RelA and the glucocorticoid receptor:
a possible mechanism for the anti-inflammatory action of
glucocorticoids. Mol Endocrinol 9:401412[Abstract]
-
Shibata H, Spencer TE, Onate SA, Jenster G, Tsai SY, Tsai MJ,
OMalley BW 1997 Role of co-activators and co-repressors in the
mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 52:14164[Medline]
-
Janknecht R, Hunter T 1996 Transcription. A growing
coactivator network. Nature 383:2223[CrossRef][Medline]
-
Hong H, Kohli K, Garabedian MJ, Stallcup MR 1997 GRIP1, a
transcriptional coactivator for the AF-2 transactivation domain of
steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 17:27352744[Abstract]
-
Drouin J, Sun YL, Chamberland M, Gauthier Y, De Lean A, Nemer
M, Schmidt TJ 1993 Novel glucocorticoid receptor complex with DNA
element of the hormone-repressed POMC gene. EMBO J 12:145156[Abstract]
-
Sakai DD, Helms S, Carlstedt-Duke J, Gustafsson JA, Rottman
FM, Yamamoto KR 1988 Hormone-mediated repression: a negative
glucocorticoid response element from the bovine prolactin gene. Genes
Dev 2:11441154[Abstract]
-
Stauber C, Altschmied J, Akerblom IE, Marron JL, Mellon PL 1992 Mutual cross-interference between glucocorticoid receptor and CREB
inhibits transactivation in placental cells. New Biol 4:527540[Medline]
-
Konig H, Ponta H, Rahmsdorf HJ, Herrlich P 1992 Interference
between pathway-specific transcription factors: glucocorticoids
antagonize phorbol ester-induced AP-1 activity without altering AP-1
site occupation in vivo. EMBO J 11:22412246[Abstract]
-
Hard T, Kellenbach E, Boelens R, Maler BA, Dahlman K, Freedman
LP, Carlstedt-Duke J, Yamamoto KR, Gustafsson JA, Kaptein R 1990 Solution structure of the glucocorticoid receptor DNA-binding domain.
Science 249:157160[Medline]
-
Imai E, Miner JN, Mitchell JA, Yamamoto KR, Granner DK 1993 Glucocorticoid receptor-cAMP response element-binding protein
interaction and the response of the phosphoenolpyruvate carboxykinase
gene to glucocorticoids. J Biol Chem 268:53535356[Abstract/Free Full Text]
-
Akerblom IE, Slater EP, Beato M, Baxter JD, Mellon PL 1988 Negative regulation by glucocorticoids through interference with a cAMP
responsive enhancer. Science 241:350353[Medline]
-
Deutsch PJ, Hoeffler JP, Jameson JL, Habener JF 1988 Cyclic
AMP and phorbol ester-stimulated transcription mediated by similar DNA
elements that bind distinct proteins. Proc Natl Acad Sci USA 85:79227926[Abstract]
-
Sassone-Corsi P, Ransone LJ, Verma IM 1990 Cross-talk in
signal transduction: TPA-inducible factor jun/AP-1 activates
cAMP-responsive enhancer elements. Oncogene 5:427431[Medline]
-
Hoeffler JP 1992 Structure/function relationships of CREB/ATF
proteins. J Invest Dermatol 98:21S28S
-
Karin M 1990 Too many transcription factors: positive and
negative interactions. New Biol 2:126131[Medline]
-
Dorin RI, Zlock DW, Kilpatrick K 1993 Transcriptional
regulation of human corticotropin releasing factor gene expression by
cyclic adenosine 3',5'-monophosphate: differential effects at proximal
and distal promoter elements. Mol Cell Endocrinol 96:99111[CrossRef][Medline]
-
Majzoub JA, Emanuel R, Adler G, Martinez C, Robinson B,
Wittert G 1993 Second messenger regulation of mRNA for
corticotropin-releasing factor. Ciba Found Symp 172:3043; discussion
4358[Medline]
-
Kushner PJ, Baxter JD, Duncan KG, Lopez GN, Schaufele F, Uht
RM, Webb P, West BL 1994 Eukaryotic regulatory elements linking in
plasmid DNA: the activator protein-1 site in pUC. Mol Endocrinol 8:405407[Medline]
-
Chalepakis G, Schauer M, Cao XA, Beato M 1990 Efficient
binding of glucocorticoid receptor to its responsive element requires a
dimer and DNA flanking sequences. DNA Cell Biol 9:355368[Medline]
-
Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin
J, Karin M 1990 Transcriptional interference between c-Jun and the
glucocorticoid receptor: mutual inhibition of DNA binding due to direct
protein-protein interaction. Cell 62:12051215[Medline]
-
Vamvakopoulos NC, Chrousos GP 1994 Hormonal regulation of
human corticotropin-releasing hormone gene expression: implications for
the stress response and immune/inflammatory reaction. Endocr Rev 15:409420[Medline]
-
Masquilier D, Sassone-Corsi P 1992 Transcriptional cross-talk:
nuclear factors CREM and CREB bind to AP-1 sites and inhibit activation
by Jun. J Biol Chem 267:2246022466[Abstract/Free Full Text]
-
Hoeffler JP, Deutsch PJ, Lin J, Habener JF 1989 Distinct
adenosine 3',5'-monophosphate and phorbol ester-responsive signal
transduction pathways converge at the level of transcriptional
activation by the interactions of DNA-binding proteins. Mol Endocrinol 3:868880[Abstract]
-
Lamph WW, Dwarki VJ, Ofir R, Montminy M, Verma IM 1990 Negative and positive regulation by transcription factor cAMP response
element-binding protein is modulated by phosphorylation. Proc Natl Acad
Sci USA 87:43204324[Abstract]
-
Benbrook DM, Jones NC 1990 Heterodimer formation between CREB
and JUN proteins. Oncogene 5:295302[Medline]
-
Iordanov M, Bender K, Ade T, Schmid W, Sachsenmaier C, Engel
K, Gaestel M, Rahmsdorf HJ, Herrlich P 1997 CREB is activated by UVC
through a p38/HOG-1-dependent protein kinase. EMBO J 16:10091022[Abstract/Free Full Text]
-
Pierrat B, Correia JS, Mary JL, Tomas-Zuber M, Lesslauer W 1998 RSK-B, a novel ribosomal S6 kinase family member, is a CREB kinase
under dominant control of p38
mitogen-activated protein kinase
(p38
MAPK). J Biol Chem 273:2966129671[Abstract/Free Full Text]
-
Zhen X, Uryu K, Wang HY, Friedman E 1998 D1 dopamine receptor
agonists mediate activation of p38 mitogen-activated protein kinase and
c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism
in SK-N-MC human neuroblastoma cells. Mol Pharmacol 54:453458[Abstract/Free Full Text]
-
Deak M, Clifton AD, Lucocq LM, Alessi DR 1998 Mitogen- and
stress-activated protein kinase-1 (MSK1) is directly activated by MAPK
and SAPK2/p38, and may mediate activation of CREB. EMBO J 17:44264441[Abstract/Free Full Text]
-
Subramaniam N, Cairns W, Okret S 1997 Studies on the mechanism
of glucocorticoid-mediated repression from a negative glucocorticoid
response element from the bovine prolactin gene. DNA Cell Biol 16:153163[Medline]
-
Freedman LP, Alroy I 1993 Gel mobility shift assay to study
nuclear hormone receptor-DNA interactions. Methods Mol Genet 1:280299
-
Maxwell IH, Harrison GS, Wood WM, Maxwell F 1989 A DNA
cassette containing a trimerized SV40 polyadenylation signal which
efficiently blocks spurious plasmid-initiated transcription.
Biotechniques 7:276280[Medline]
-
Nordeen SK 1988 Luciferase reporter gene vectors for analysis
of promoters and enhancers. Biotechniques 6:454457[Medline]
-
Kay TWH, Jameson JL 1992 Identification of a
gonadotropin-releasing hormone-responsive region in the glycoprotein
hormone a-subunit promoter. Mol Endocrinol 6:17671773[Abstract]
-
Giguere V, Hollenberg SM, Rosenfeld MG, Evans RM 1986 Functional domains of the human glucocorticoid receptor. Cell 46:645652[Medline]